Literature DB >> 18819329

Epidemiology of gout.

Arthur L Weaver1.   

Abstract

The incidence and prevalence of gout are rising, likely as a result of a changing pattern of risk factors. At-risk populations are growing, due to the fact that people are living longer. Longevity and current dietary and lifestyle choices have also contributed to increased rates of comorbidities associated with hyperuricemia and gout. The use of medications to treat such comorbidities also plays a role in some cases of gout. While dietary and lifestyle modification may be useful as adjunctive measures, such changes do not replace pharmacologic treatments for gout or associated comorbidities.

Entities:  

Mesh:

Year:  2008        PMID: 18819329     DOI: 10.3949/ccjm.75.suppl_5.s9

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  27 in total

1.  Efficacy and safety of febuxostat in patients with hyperuricemia and gout.

Authors:  Ignacio Garcia-Valladares; Tahir Khan; Luis R Espinoza
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-10       Impact factor: 5.346

2.  Uric Acid and Cardiovascular Events: A Mendelian Randomization Study.

Authors:  Marcus E Kleber; Graciela Delgado; Tanja B Grammer; Günther Silbernagel; Jie Huang; Bernhard K Krämer; Eberhard Ritz; Winfried März
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

Review 3.  A Systematic Review of the Economic and Humanistic Burden of Gout.

Authors:  Gemma E Shields; Stephen M Beard
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

4.  Pegloticase for treatment of tophaceous polyarticular gout.

Authors:  Rebecca M Seifried; Jefferson Roberts
Journal:  Hawaii J Med Public Health       Date:  2013-07

5.  Incidence of inflammatory joint diseases in Finland: results from a population-based epidemiological study.

Authors:  A Kononoff; L Arstila; P Pussinen; H Kautiainen; P Elfving; E Savolainen; H Niinisalo; J Rutanen; O Marjoniemi; O Kaipiainen-Seppänen
Journal:  Rheumatol Int       Date:  2017-08-08       Impact factor: 2.631

6.  No evidence for involvement of the toll-like receptor (TLR) 4 gene Asp299Gly and Thr399Ile polymorphisms in susceptibility to primary gouty arthritis.

Authors:  Yu-Feng Qing; Jing-Guo Zhou; Ming Li; Wen-Guang Xie; Cui-Ping Huang; Sheng-Ping Zeng; Ling Yin
Journal:  Rheumatol Int       Date:  2012-11-15       Impact factor: 2.631

7.  Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study.

Authors:  Lili Zhang; Kylee L Spencer; V Saroja Voruganti; Neal W Jorgensen; Myriam Fornage; Lyle G Best; Kristin D Brown-Gentry; Shelley A Cole; Dana C Crawford; Ewa Deelman; Nora Franceschini; Angelo L Gaffo; Kimberly R Glenn; Gerardo Heiss; Nancy S Jenny; Anna Kottgen; Qiong Li; Kiang Liu; Tara C Matise; Kari E North; Jason G Umans; W H Linda Kao
Journal:  Am J Epidemiol       Date:  2013-04-03       Impact factor: 4.897

8.  Changes in toll-like receptor (TLR)4-NFκB-IL1β signaling in male gout patients might be involved in the pathogenesis of primary gouty arthritis.

Authors:  Yu-Feng Qing; Quan-Bo Zhang; Jing-Guo Zhou; Li Jiang
Journal:  Rheumatol Int       Date:  2013-09-14       Impact factor: 2.631

Review 9.  Gout--current diagnosis and treatment.

Authors:  Anne-Kathrin Tausche; Tim L Jansen; Hans-Egbert Schröder; Stefan R Bornstein; Martin Aringer; Ulf Müller-Ladner
Journal:  Dtsch Arztebl Int       Date:  2009-08-24       Impact factor: 5.594

10.  IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response.

Authors:  Mei Zeng; Wantai Dang; Baofeng Chen; Yufeng Qing; Wenguang Xie; Mingcai Zhao; Jingguo Zhou
Journal:  Clin Rheumatol       Date:  2015-11-07       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.